Rachel Warren

Comparable sales dropped.

Both gap and adjusted earnings were down.

Gap earnings per share actually fell about 19%.

Target's chief commercial officer noted that consumers are prioritizing gift-giving over other holiday spending, but broadly signaled that they expect a weak holiday spending season, even as they're introducing 20,000 or more new items across various categories.

And they're forecasting an ongoing sales slump.

Now, contrast that to a business like TJX Companies.

Obviously, the business models of these companies are different, but still, there could not be more variance.

Absolutely.

Where you've got Target forecasting a week holiday season, sales are down.

The CEO of TGX Company said, the holiday shopping season is off to a strong start for us.

They said, our availability of merchandise is outstanding.

We're really excited about the deals that we're seeing.

They're expecting comparable sales to rise between 2% and 3%.

They even elevated their upcoming expectations after their better-than-expected Q3 results.

A really strong quarter for TGX companies, a very weak quarter for Target.

I think what we're seeing is, maybe consumer weaknesses persist, but how that plays out to different companies is going to be on a very much case-by-case basis.

This is an area that Pfizer has wanted to expand into for a while now.

You might remember at one point, they actually had their own GLP-1 candidate.

They had to discontinue that back in April of this year.

There had been a bidding war that essentially erupted between Pfizer and Novonordisk for Metzera.